Skip to main content
MLYS
NASDAQ Life Sciences

RA Capital Funds, Directors Buy $8.76M in Mineralys Therapeutics Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$28.75
Mkt Cap
$2.232B
52W Low
$10.44
52W High
$47.65
52W Position info
175% above low
Off High info
40% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

MLYS has more than doubled off its 52-week low of $10.44 on elevated volume (2.0× avg).

Summary

RA Capital Healthcare Fund LP and affiliated entities, including directors Peter Kolchinsky and Rajeev Shah, made significant open market purchases of Mineralys Therapeutics common stock totaling $8.76 million.


Key Events · Ownership and Investor Activity · MLYS

  • Significant Insider Purchase

    RA Capital Healthcare Fund LP and its affiliates, including directors Peter Kolchinsky and Rajeev Shah, acquired 369,000 shares of Mineralys Therapeutics common stock.

  • Substantial Investment Value

    The open market purchases totaled $8,762,797, executed between March 27 and March 30, 2026, at prices ranging from $23.67 to $24.16 per share.

  • Institutional Confidence

    This transaction by a major institutional investor with board representation indicates strong belief in the company's prospects, particularly following the recent FDA NDA acceptance for lorundrostat.


Analysis · MLYS · Life Sciences

This substantial open market purchase by RA Capital, a major institutional investor with board representation, signals strong conviction in Mineralys Therapeutics. The acquisition of nearly $8.8 million in shares, representing a notable percentage of the company's market capitalization, suggests that key insiders associated with the fund see significant value at current price levels. This comes after the company's recent 10-K filing confirmed FDA acceptance of its NDA for lorundrostat, with a PDUFA date set for December 2026, indicating confidence ahead of a critical regulatory milestone.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLYS was trading at $28.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $10.44 to $47.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLYS - Latest Insights

MLYS
Nov 04, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.82
Real-time Price: $15.29 info
Change: -$1.53 (-9%) info
Market Cap: $1.347B info
MLYS
Nov 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.16
Real-time Price: $15.29 info
Change: -$1.87 (-11%) info
Market Cap: $1.347B info
MLYS
Oct 29, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.24
Real-time Price: $15.29 info
Change: -$5.95 (-28%) info
Market Cap: $1.347B info
MLYS
Oct 28, 2026, 7:05 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $21.30
Real-time Price: $15.29 info
Change: -$6.01 (-28%) info
Market Cap: $1.347B info
MLYS
Oct 22, 2026, 6:40 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $21.47
Real-time Price: $15.29 info
Change: -$6.18 (-29%) info
Market Cap: $1.347B info